US-based healthcare performance improvement company Vizient has awarded a contract to Surfacide for UV-C solution that can help hospitals combat Covid-19.

Vizient serves more than half of the healthcare organizations across the country from large integrated delivery networks and academic medical centres to community hospitals, paediatric facilities and non-acute care providers.

Under the contract, Vizient members will get access to Surfacide’s multiple emitter UV-C solution that has become an integral part to protect patients as well as staff during uncertain times.

Surfacide founder and CEO Gunner Lyslo said: “Surfacide is proud of this contract with Vizient and proud to answer the urgent call from countless healthcare facilities that need a solution they can trust to deliver protection for healthcare workers and patients.

“Over the course of the last few months, we’ve seen UV-C technology emerge as a key tactic in combating coronavirus and other infections.”

The Surfacide solution is being deployed in facilities across the US as organisations implement solutions in the fight against the pandemic.

The UV-C solution system provides an automated UV-C decontamination technology that is capable of reducing bacteria, spores and viruses. It is also effective against various advanced viral infectious diseases.

Multiple automated UV-C emitters within the Helios work together and provide decontamination of the room in a short span of time offering an extra layer of protection.

Lyslo further added: “We are confident that Surfacide’s agreement with Vizient will allow more healthcare centres to have access to the Surfacide UV-C solution and slow the spread of Covid-19.”